Clinical trials data
Verbal Fluency in Parkinson's disease trials: 140 registered studies
Every registered Parkinson's disease study on ClinicalTrials.gov that names Verbal Fluency in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered Parkinson's disease studies name it in an outcome measure
- 140
- Name it in a primary outcome, 32%
- 45 of 140
Tests named in the same studies
- 1
Trail Making Test50 studies, 10 as a primary outcome
- 2
Digit Span Test43 studies, 6 as a primary outcome
- 3
Stroop Color-Word Test42 studies, 11 as a primary outcome
- 4
Verbal Learning33 studies, 11 as a primary outcome
- 5
Category Fluency29 studies, 10 as a primary outcome
- 6
Picture Naming Test25 studies, 2 as a primary outcome
- 7
Clock Drawing Task18 studies, 3 as a primary outcome
- 8
Symbol Coding17 studies, 4 as a primary outcome
- 9
Line Angle Matching15 studies, 3 as a primary outcome
- 10
Card Sorting Test (Berg)13 studies, 4 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 3 | 1 |
| 2012 | 4 | 1 |
| 2013 | 4 | 0 |
| 2014 | 6 | 2 |
| 2015 | 2 | 0 |
| 2016 | 7 | 1 |
| 2017 | 12 | 2 |
| 2018 | 12 | 2 |
| 2019 | 10 | 6 |
| 2020 | 12 | 5 |
| 2021 | 14 | 5 |
| 2022 | 12 | 2 |
| 2023 | 10 | 6 |
| 2024 | 9 | 4 |
| 2025 | 10 | 4 |
| 2026 | 11 | 4 |
Phases and study sizes
By phase
- Early phase 13 studies, 0 as a primary outcome
- Phase 14 studies, 0 as a primary outcome
- Phase 1/22 studies, 2 as a primary outcome
- Phase 214 studies, 2 as a primary outcome
- Phase 32 studies, 0 as a primary outcome
- Phase 43 studies, 1 as a primary outcome
- Not applicable87 studies, 26 as a primary outcome
- Observational25 studies, 14 as a primary outcome
Participants per study
- Phase 267 median, 31 to 117
- Not applicable34 median, 21 to 65
- Observational100 median, 52 to 163
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 14 | 67 | 31 to 117 |
| Not applicable | 86 | 34 | 21 to 65 |
| Observational | 24 | 100 | 52 to 163 |
When Parkinson's disease trials measure it
Latest time point of each outcome
- Within a day25 outcomes, 10 as a primary outcome
- Up to 4 weeks19 outcomes, 5 as a primary outcome
- 1 to 3 months44 outcomes, 13 as a primary outcome
- 3 to 6 months23 outcomes, 5 as a primary outcome
- 6 to 12 months8 outcomes, 1 as a primary outcome
- 1 to 2 years6 outcomes, 3 as a primary outcome
- Over 2 years7 outcomes, 3 as a primary outcome
- No duration given8 outcomes, 5 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
132 of the 140 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting27 studies, 14 as a primary outcome
- Not yet recruiting2 studies, 1 as a primary outcome
- Active, not recruiting5 studies, 1 as a primary outcome
- Completed64 studies, 21 as a primary outcome
- Stopped early10 studies, 3 as a primary outcome
- Status unknown32 studies, 5 as a primary outcome
What they test
- Behavioral27 studies, 5 as a primary outcome
- Drug22 studies, 4 as a primary outcome
- Device42 studies, 10 as a primary outcome
- Dietary supplement2 studies, 1 as a primary outcome
- Procedure7 studies, 2 as a primary outcome
- Diagnostic test10 studies, 7 as a primary outcome
- Biological1 studies, 1 as a primary outcome
- Radiation2 studies, 2 as a primary outcome
- Genetic2 studies, 1 as a primary outcome
- Other47 studies, 20 as a primary outcome
- None given6 studies, 3 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States46 studies, 19 as a primary outcome
- Brazil12 studies, 4 as a primary outcome
- Italy12 studies, 3 as a primary outcome
- Canada8 studies, 1 as a primary outcome
- Netherlands8 studies, 0 as a primary outcome
- Türkiye8 studies, 5 as a primary outcome
- Sweden7 studies, 1 as a primary outcome
- Taiwan7 studies, 0 as a primary outcome
- United Kingdom7 studies, 2 as a primary outcome
- China6 studies, 2 as a primary outcome
- Germany6 studies, 1 as a primary outcome
- Spain6 studies, 3 as a primary outcome
32 countries in all. A study with sites in several counts in each; 6 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed Parkinson's disease studies that name Verbal Fluency: 33 of 64, 52%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed Parkinson's disease studies that name Verbal Fluency | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 9, 14% | 776, 10% |
| Results on ClinicalTrials.gov only | 13, 20% | 1,139, 14% |
| A results paper only | 11, 17% | 1,711, 22% |
| Neither | 31, 48% | 4,327, 54% |
The 140 studies
140 studies match. 45 name Verbal Fluency in a primary outcome. Median size 44 participants. Median time to the primary outcome: 12 weeks.
Loading 140 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 3 | 1 |
| 2012 | 4 | 1 |
| 2013 | 4 | 0 |
| 2014 | 6 | 2 |
| 2015 | 2 | 0 |
| 2016 | 7 | 1 |
| 2017 | 12 | 2 |
| 2018 | 12 | 2 |
| 2019 | 10 | 6 |
| 2020 | 12 | 5 |
| 2021 | 14 | 5 |
| 2022 | 12 | 2 |
| 2023 | 10 | 6 |
| 2024 | 9 | 4 |
| 2025 | 10 | 4 |
| 2026 | 11 | 4 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 9, other 131. Interventional 115, observational 25.
As a primary outcomeSecondary or other outcomeVerbal Fluency
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07832695 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants90 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07815964 | Start2026 | PhaseObservational | ConditionsParkinson's disease | Participants100 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07777419 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07678983 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants66 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07651085 | Start2024 | PhaseObservational | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease, Sleep and sleep disorders | Participants65 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07569120 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease, Healthy volunteers, Aging, frailty and exercise | Participants165 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07536022 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants16 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07534397 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07456475 | Start2025 | PhaseNot applicable | ConditionsStroke, Brain injury and concussion, Parkinson's disease, Multiple sclerosis | Participants25 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07355842 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease, Sleep and sleep disorders | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07340073 | Start2026 | PhasePhase 1 | ConditionsParkinson's disease | Participants24 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07277205 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease | Participants45 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07262658 | Start2022 | PhaseObservational | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07240272 | Start2023 | PhaseNot applicable | ConditionsParkinson's disease | Participants28 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07154511 | Start2025 | PhasePhase 1/2 | ConditionsDementia and Alzheimer's, Parkinson's disease | Participants45 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07058714 | Start2025 | PhaseObservational | ConditionsParkinson's disease | Participants30 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07055087 | Start2026 | PhasePhase 2 | ConditionsParkinson's disease | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06967493 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06960096 | Start2025 | PhaseObservational | ConditionsParkinson's disease | Participants55 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06906276 | Start2025 | PhaseObservational | ConditionsParkinson's disease, Aging, frailty and exercise | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06893120 | Start2022 | PhaseNot applicable | ConditionsParkinson's disease, Depression and bipolar disorder | Participants20 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06823921 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06782724 | Start2025 | PhasePhase 2 | ConditionsParkinson's disease, Multiple sclerosis, Depression and bipolar disorder, Lung disease | Participants108 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06688357 | Start2019 | PhaseNot applicable | ConditionsParkinson's disease | Participants23 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06657274 | Start2024 | PhaseNot applicable | ConditionsMild cognitive impairment, Parkinson's disease | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
Questions, answered from the data
How many Parkinson's disease trials use Verbal Fluency?
140 registered Parkinson's disease studies on ClinicalTrials.gov name it in an outcome measure, 45 of them in a primary outcome: 16% of the condition's 892 studies with a cognitive outcome, against 11% of all of them. It is the 2nd most named test in Parkinson's disease trials.
Which tests do Parkinson's disease trials use with Verbal Fluency?
The Trail Making Test (50 studies), the Digit Span Test (43 studies) and the Stroop Color-Word Test (42 studies).
How many participants do phase 2 Parkinson's disease trials that use Verbal Fluency enroll?
Half of the phase 2 studies that name it enroll 67 participants or fewer, and the middle half enroll 31 to 117. 14 of them give a size.
When do Parkinson's disease trials measure Verbal Fluency?
Half of the primary outcomes that name Verbal Fluency are measured within 12 weeks of the start, and the middle half from 5 days to 4 months. 40 primary outcomes give a duration.
How many completed Parkinson's disease trials that use Verbal Fluency have reported results?
33 of the 64 completed studies that name it, 52%, have reported results: 22 posted them on ClinicalTrials.gov, 20 have a results paper linked to the registry record, and 9 did both. The other 31 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
Run Verbal Fluency in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.